FY2026 EPS Estimate for Urogen Pharma Raised by Analyst

Urogen Pharma (NASDAQ:URGN) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Urogen Pharma in a note issued to investors on Thursday, November 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.77) per share for the year, up from their previous estimate of ($0.83). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2026 earnings at $0.02 EPS, Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.21 EPS, Q4 2027 earnings at $0.28 EPS and FY2027 earnings at $0.59 EPS.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to analyst estimates of $89.92 million.

A number of other brokerages also recently weighed in on URGN. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Jefferies Financial Group reissued a “buy” rating and set a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. Oppenheimer set a $60.00 price target on Urogen Pharma in a report on Thursday. TD Cowen upped their price objective on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, UBS Group reaffirmed an “outperform” rating on shares of Urogen Pharma in a research note on Thursday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $53.38.

Urogen Pharma Stock Performance

Shares of URGN opened at $26.31 on Monday. The firm has a 50 day simple moving average of $38.44 and a two-hundred day simple moving average of $31.56. Urogen Pharma has a one year low of $16.50 and a one year high of $50.81.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Smith sold 1,519 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the transaction, the general counsel owned 53,141 shares of the company’s stock, valued at $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares of the company’s stock, valued at $2,570,135.44. This represents a 1.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 65,269 shares of company stock worth $3,037,646. Insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. BlackRock Inc. bought a new position in shares of Urogen Pharma during the second quarter valued at $117,814,000. Jefferies Financial Group Inc. bought a new stake in shares of Urogen Pharma in the second quarter worth $80,947,000. Bank of America Corp DE bought a new stake in shares of Urogen Pharma in the second quarter worth $17,506,000. Rice Hall James & Associates LLC acquired a new stake in Urogen Pharma in the second quarter valued at $11,064,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Urogen Pharma in the second quarter valued at $9,288,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer.

The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.